Every 8-K that Cassava Sciences, Inc. (SAVA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow SAVA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full SAVA filings page.
Filana Therapeutics reported Q1 2026 results showing sharply lower expenses and a smaller loss as it pivots to TSC-related epilepsy. Net loss was $10.3 million, or $0.21 per share, versus $23.4 million, or $0.48, a year earlier.
Research and development spending fell to $4.5 million from $13.7 million, a 67% decrease driven by phasing out the Alzheimer’s program. General and administrative costs declined to $6.6 million from $10.9 million, partly because a $3.0 million legal loss contingency booked in Q1 2025 did not recur.
Cash and cash equivalents were $86.6 million at March 31, 2026, with no debt, and the company estimates cash at June 30, 2026 in a range of $47–$50 million. Guidance includes net cash used in operations of $14–$17 million for first-half 2026 plus an expected $31.25 million loss contingency payment related to potential settlement of certain securities litigation.
Filana Therapeutics, Inc. reported that board member Michael O’Donnell has decided to resign from its Board of Directors, effective at the conclusion of the Company’s 2026 annual meeting of stockholders. He will continue to serve as a director until that meeting is completed.
The Company stated that Mr. O’Donnell’s resignation is not due to any disagreement with Filana Therapeutics, its management, or the Board regarding operations, policies, or practices. The report was signed on behalf of the Company by Chief Financial Officer Eric J. Schoen.
Filana Therapeutics reported a 2025 net loss of $91.0 million, or $1.88 per share, as it repositions around TSC-related epilepsy and other filamin A–driven CNS disorders. The wider loss versus 2024 mainly reflects a $108.1 million non‑recurring gain on warrant liabilities in the prior year.
Cash and cash equivalents were $95.5 million with no debt as of December 31, 2025, after $32.3 million of net cash used in operations. The company estimates cash of $47–$50 million as of June 30, 2026 and expects first-half 2026 operating cash use of $14–$17 million plus a $31.25 million payment tied to an estimated securities litigation loss contingency recorded in 2025.
Filana reduced annual R&D expenses to $26.6 million from $69.6 million, a 62% cut driven by phasing out its Alzheimer’s disease program, and expects its planned TSC-related epilepsy clinical program to cost significantly less. G&A expenses decreased slightly to $68.8 million, reflecting shifting litigation contingencies and higher stock-based compensation. The company is addressing FDA requests in connection with a full clinical hold on its simufilam IND in TSC-related epilepsy and plans to respond as soon as practicable.
Cassava Sciences, Inc. has changed its legal name to Filana Therapeutics, Inc. effective March 10, 2026, through a Certificate of Amendment filed in Delaware. The board also adopted amended and restated bylaws that update provisions on shareholder and board meetings, advance notice, director terms, special meetings, inspectors of election, and uncertificated shares.
Beginning March 11, 2026, the company’s common stock will trade on the Nasdaq Capital Market under the new ticker symbol FLNA. The corporate website has moved from cassavasciences.com to filanatx.com, where investors can access SEC filings, governance documents, and future Code of Conduct updates.
A press release explains that the new Filana Therapeutics identity aligns with a strategic focus on developing investigational therapies that modulate the filamin A protein to treat central nervous system disorders such as TSC-related epilepsy and other diseases linked to filamin A dysregulation.
Cassava Sciences, Inc. reported that the U.S. Department of Justice Fraud Section has closed its inquiry into the company regarding previously disclosed allegations of research misconduct connected to the case United States v. Wang, whose indictment was dismissed with prejudice on October 23, 2025. The company also highlighted that it had earlier resolved negligence-based disclosure charges with the U.S. Securities and Exchange Commission in September 2024 by paying a monetary penalty without admitting or denying the SEC’s allegations. These outcomes conclude the DOJ and SEC investigations of Cassava, allowing management to emphasize a continued focus on developing novel investigational treatments, including simufilam, for central nervous system disorders such as tuberous sclerosis complex-related epilepsy.
Cassava Sciences, Inc. has agreed to a mediated settlement in a federal securities class action pending in the U.S. District Court for the Western District of Texas. Under a binding term sheet, Cassava and its CFO, Eric J. Schoen, will pay $31.25 million into escrow, expected in January 2026, to obtain a complete settlement of all claims by a class of investors who traded Cassava common stock and certain options between September 14, 2020 and October 12, 2023.
The settlement will provide full and complete releases for Cassava, Mr. Schoen, and two other indemnified officers, with all claims against the non-settling individuals to be dismissed with prejudice upon final court approval. Cassava noted that it had already recorded a $31.25 million loss contingency in the second quarter of 2025 related to this matter, meaning the financial charge has been previously recognized. The settlement expressly does not constitute an admission of fault or wrongdoing by the company.
Cassava Sciences, Inc. reports that the U.S. Food and Drug Administration has placed its proposed proof-of-concept clinical trial of simufilam in tuberous sclerosis complex (TSC)-related epilepsy on a full clinical hold. FDA’s letter requires Cassava to provide additional information, including more pre-clinical data, and to modify the trial’s protocol design before the study can proceed. Cassava plans to work expeditiously to address FDA’s comments, but it no longer expects to start this TSC-related epilepsy trial in the first half of 2026 as previously disclosed. The timing for starting a trial will depend on the company’s ability to provide the requested information and on FDA completing its review to the agency’s satisfaction.
Cassava Sciences, Inc. reported that its Board of Directors approved cash bonus awards for calendar 2025 for two named executive officers. The President & Chief Executive Officer, Richard J. Barry, was awarded a cash bonus of $355,000, and the Chief Financial Officer, Eric J. Schoen, was awarded a cash bonus of $215,000, in recognition of their contributions to the company.
For 2025, the Board set performance measures and goals that it described as challenging yet achievable with strong management performance. These goals focus on exploring the use of simufilam in Tuberous Sclerosis Complex (TSC)-related epilepsy, building a team with appropriate expertise in TSC-related epilepsy, and managing budgeting and expenses.
Cassava Sciences, Inc. filed a current report to note that it released a press release on November 12, 2025 covering its results of operations and financial condition. The company attached this press release as Exhibit 99.1 and stated that the information is being furnished, not filed, which limits how it is treated under securities law. The filing also identifies Cassava’s common stock, par value $0.001, as trading under the symbol SAVA on the NASDAQ Capital Market.
Cassava Sciences reported a legal update: on October 23, 2025, the U.S. District Court for the District of Maryland dismissed with prejudice the criminal indictment of Dr. Hoau‑Yan Wang, a former scientific collaborator and advisor to the company. A dismissal with prejudice permanently ends the case and prevents refiling of the same charges.
The company emphasized its support for scientific integrity and noted it is continuing its current program evaluating simufilam as a potential treatment for TSC‑related epilepsy, citing research conducted at numerous institutions. This update addresses a key legal overhang involving a third party while the company maintains focus on its development work.
Cassava Sciences expanded its Board of Directors to eight members and appointed Dawn Carter Bir as a Class I director, effective October 21, 2025. Her term will expire at the Company’s 2028 annual meeting of stockholders.
The Company stated there are no arrangements or understandings behind the appointment and no related‑party transactions requiring disclosure. Ms. Bir was made eligible for compensation under the Non‑employee Director Compensation Program and signed the Company’s standard indemnification agreement. A press release announcing the appointment was furnished as Exhibit 99.1.
Cassava Sciences, Inc. filed a current report to furnish its latest corporate presentation under Regulation FD. The presentation, dated September 2025, is made available as Exhibit 99.1 and is also posted in the Investors section of the company’s website. The company states that this material is being furnished rather than filed, meaning it is not subject to certain liability provisions of the Exchange Act and will not be automatically incorporated into other securities law filings.
Cassava Sciences, Inc. furnished an 8-K related to its results of operations and financial condition. On August 14, 2025, the company issued a press release, which is attached as Exhibit 99.1 and incorporated by reference. The press release contains the detailed financial and operating information.
The company specifies that the information in this report, including Exhibit 99.1, is being furnished and not filed under the Securities Exchange Act of 1934, which limits its use for certain legal liability purposes and for incorporation by reference into other securities filings.
Cassava Sciences (SAVA) filed an 8-K to disclose positive preclinical data for simufilam in tuberous sclerosis complex (TSC)-related epilepsy. In a Tsc1 conditional knockout mouse model that develops spontaneous seizures, multiple doses of simufilam were tested over ~3 weeks. The compound significantly reduced seizure progression in a dose-dependent manner; other measured endpoints did not reach significance.
The study was run with the TSC Alliance and PsychoGenics under the TSC Preclinical Consortium. Management plans to present full data at a scientific meeting and initiate the first human proof-of-concept trial in H1 2026. No financial terms, revenue impact, or guidance were provided. Item 7.01 makes the accompanying press release furnished, not filed.
Key takeaways:
- Preclinical efficacy signal supports simufilam’s mechanism beyond Alzheimer’s.
- Expands pipeline into rare-disease epilepsy market.
- Tight timeline sets a near-term catalyst but still carries high development risk.